ImmoGnost GmbH

ImmoGnost GmbH is the future-oriented joint venture of the companies Fassisi GmbH (development and production of on-site rapid test systems for the veterinary sector) and miprolab GmbH (microbiological diagnostics and detection of biological warfare agents, bacteria, viruses, toxins and metabolites) and specialises in lateral flow analysis (LFA).

The two parent companies are based in Göttingen and have more than 10 years of experience in the development, production and use of rapid test systems for veterinary and human applications. Fassisi GmbH and miprolab GmbH have always been committed to cooperation in their work and are active in diagnostics networks from the biotech sector. This has already led to the production of the RACORDIAX COVID-19 antibody rapid test. Fassisi GmbH has several years of experience in the development of rapid test systems for coronaviruses from the development and production of a MERS-CoV rapid test (MERS: Middle East Respiratory Syndrome Coronavirus) for camels.

Development, production and certification in Germany

The managing directors of ImmoGnost GmbH, Stephan Sander (Fassisi GmbH) and Dr Frank Gessler (miprolab GmbH), were quick to realise that there was more to come. The challenges presented by the SARS-CoV-2 pandemic for people, the economy and society have called for what ImmoGnost GmbH has since achieved using the highest process quality: the precise point-of-care diagnostic test ImmoGnost SARS-CoV-2 (COVID-19) rapid test has been launched on the market – developed, produced and certified in Germany. The ImmoGnost SARS-CoV-2 (COVID-19) Rapid Test remains the first and only antigen rapid test made in Germany for which all critical starting materials of the test also originate from Germany. This unique selling point and the very high quality and precision of the test make the ImmoGnost SARS-CoV-2 (COVID-19) Rapid Test a pioneer among rapid antigen tests.

Highest standards throughout the process

For ImmoGnost GmbH, the COVID-19 pandemic and the development of the ImmoGnost SARS-CoV-2 antigen rapid test has been the catalyst for embarking on a future as a leading company with a promise to deliver quality in human diagnostics. Other human rapid test systems are already being developed and will soon be market-ready. The focus is always on maintaining the highest standards throughout the entire process – from the raw materials to the production location in Germany through to the accuracy of the tests.